Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/TRex Bio, Inc./ S-8

SEC Filing · S-8

TRex Bio, Inc.

TRXBNASDAQEQUITYCurrent

SEC Filing

Filed Oct 9, 2026Accepted Oct 9, 2026, 5:22 PM EDTCIK 2139097Accession 0001193125-26-419221
View company →Permanent SEC source ↗
Share

Company context

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair. Leveraging our Deep Biology drug discovery and design platform, we integrate tissue-level insights into human biology and Treg function to identify and characterize novel targets and approaches for therapeutic intervention. Our tissue-first conviction and unique insights in Treg biology are the foundation of our pipeline of therapeutic candidates aimed at restoring immune balance and promoting tissue repair for more durable disease control.

Current securities

TRXBNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by PFIZER INC regarding TRex Bio, Inc.Oct 16, 2026
  2. SCHEDULE 13D - filed by ELI LILLY & Co regarding TRex Bio, Inc.Oct 16, 2026
  3. SCHEDULE 13D - filed by SV Biotech Crossover Opportunities Fund LP regarding TRex Bio, Inc.Oct 16, 2026
  4. 4 filingOct 15, 2026
  5. SCHEDULE 13G - filed by Johnson & Johnson Innovation - JJDC, Inc. regarding TRex Bio, Inc.Oct 15, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.